← Back to Search

Cancer Vaccine

Autophagosome Vaccine + Immunotherapy for Head and Neck Cancer

Phase 1
Recruiting
Research Sponsored by Providence Health & Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Serum creatinine clearance ≥ 50 mL/min measured or calculated by Cockcroft-Gault (C-G) equation
Patients positive for hepatitis B core antibody (anti-HBc, total), are eligible only if HBV DNA is non-detectable by qPCR.
Must not have
History of organ transplant, including allogeneic stem cell transplantation
History of another primary malignancy except for:
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year, 2 years, and study completion
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new combination of drugs to treat head and neck cancer that has come back or spread. The new drugs are being tested to see if they are safe and effective.

Who is the study for?
Adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who are in relatively good health, as indicated by ECOG performance status of 0-2. They must have adequate organ function, no major surgeries within the last month, not be on high-dose steroids for autoimmune diseases, and cannot be pregnant or fathering a child without using contraception. HIV-positive patients can join if they're stable on antiretroviral therapy.
What is being tested?
The trial is testing a new cancer vaccine called DPV-001 combined with an anti-PD-1 immunotherapy drug named INCMGA00012. Some participants will also receive INCAGN01876, which activates immune cells via GITR to see if it enhances treatment effects against HNSCC. The study has two arms comparing these treatments.
What are the potential side effects?
Possible side effects include reactions at the injection site, flu-like symptoms such as fever and chills, fatigue, changes in blood counts leading to increased infection risk or bleeding problems. There may also be risks related to activating the immune system that could cause inflammation in various organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidneys work well enough to clear waste from my blood.
Select...
I have hepatitis B but my viral load is undetectable.
Select...
I am 18 years old or older.
Select...
I have hepatitis C but my viral load is undetectable.
Select...
I have hepatitis C but my viral load is undetectable.
Select...
My cancer is a recurring or spreading head and neck squamous cell carcinoma.
Select...
I am able to care for myself and perform daily activities.
Select...
I am 18 years old or older.
Select...
I have hepatitis B but my viral load is undetectable.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had an organ or stem cell transplant.
Select...
I have had cancer before, but it was a different type than my current diagnosis.
Select...
I had a severe reaction to previous immunotherapy that required stopping the treatment or long-term immune suppression.
Select...
I haven't had extensive radiation to my bone marrow or wide field radiation in the last 4 weeks.
Select...
I do not have any serious illnesses that my doctor thinks could interfere with the study.
Select...
I had skin cancer (not melanoma) treated and currently show no signs of it.
Select...
I take more than 10 mg/day of prednisone or equivalent for an autoimmune disease.
Select...
My early-stage cancer was treated successfully with no signs of disease.
Select...
I have had cancer spread to the lining of my brain and spinal cord.
Select...
I do not have an active tuberculosis infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year, 2 years, and study completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year, 2 years, and study completion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events Assessment
Secondary study objectives
Duration of disease control
ORR, DOR, DCR
Overall survival (OS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2 (CLOSED TO ENROLLMENT)Experimental Treatment3 Interventions
Vax + anti-GITR + delayed anti-PD-1
Group II: Arm 1Experimental Treatment2 Interventions
Vax + delayed anti-PD-1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INCAGN01876
2016
Completed Phase 2
~250
Retifanlimab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Providence Health & ServicesLead Sponsor
123 Previous Clinical Trials
823,621 Total Patients Enrolled

Media Library

DPV-001 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04470024 — Phase 1
Head and Neck Cancers Research Study Groups: Arm 2 (CLOSED TO ENROLLMENT), Arm 1
Head and Neck Cancers Clinical Trial 2023: DPV-001 Highlights & Side Effects. Trial Name: NCT04470024 — Phase 1
DPV-001 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04470024 — Phase 1
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top